Atyr PHARMA (NASDAQ:ATYR – Get Free Report) and CG Oncology (NASDAQ:CGON – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Insider & Institutional Ownership
61.7% of Atyr PHARMA shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 3.7% of Atyr PHARMA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Atyr PHARMA and CG Oncology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Atyr PHARMA | 0 | 0 | 4 | 0 | 3.00 |
| CG Oncology | 0 | 0 | 8 | 1 | 3.11 |
Profitability
This table compares Atyr PHARMA and CG Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Atyr PHARMA | N/A | -79.44% | -59.16% |
| CG Oncology | -10,642.98% | -18.97% | -15.36% |
Valuation & Earnings
This table compares Atyr PHARMA and CG Oncology”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Atyr PHARMA | $235,000.00 | 1,293.06 | -$50.39 million | ($0.94) | -3.85 |
| CG Oncology | $684,000.00 | 3,188.26 | -$48.61 million | N/A | N/A |
CG Oncology has higher revenue and earnings than Atyr PHARMA.
Summary
CG Oncology beats Atyr PHARMA on 8 of the 12 factors compared between the two stocks.
About Atyr PHARMA
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
About CG Oncology
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.
